Treatment with guselkumab (Tremfya) was effective in resolving enthesitis among patients with psoriatic arthritis (PsA), a post-hoc analysis of two phase III trials found. At week 24, 45% of patients ...

Please provide your email address to receive an email when new articles are posted on . Treatment with guselkumab results in higher enthesitis resolutions rates at week 24, with maintenance of those ...

Patients with psoriatic arthritis with enthesitis are more likely to have severe disease than patients without enthesitis, and they and their physicians are less likely to be satisfied with their ...

Patients with ankylosing spondylitis taking secukinumab saw improvements in enthesitis, and some achieved complete resolution, suggesting the drug could be a viable option for patients intolerant of ...

VIENNA — The investigational interleukin (IL)-17 inhibitor izokibep hit its mark when it came to improving overall disease activity in people with active psoriatic arthritis (PsA) in a phase 2b/3 ...

Please provide your email address to receive an email when new articles are posted on . Patients receiving tofacitinib had fewer enthesitis relapses following initial resolution after 1 or 3 months.

Around 5% of patients treated with dupilumab (Dupixent) for moderate-to-severe atopic dermatitis experience musculoskeletal (MSK) symptoms, according to the results of a descriptive study. The main ...

Certain new concepts in joint disease are gradually being introduced and treated. One such painful condition is named ‘enthesitis’. Although not exactly a type of ‘arthritis’, enthesitis could be ...

The approval was based on data from the 2-year phase 3 JUNIPERA study that evaluated secukinumab in pediatric patients aged 2 to 17 years with a confirmed diagnosis of ERA or JPsA. The Food and Drug ...

Secukinumab (Cosentyx) failed to resolve Achilles tendon inflammation in spondyloarthritis patients in the ACHILLES trial. Enthesitis resolved in the affected foot by week 24 in 42.2% of patients ...

No new safety concerns were observed through 16 weeks among pediatric patients with juvenile psoriatic arthritis or enthesitis-related arthritis receiving ixekizumab. Ixekizumab (IXE) demonstrated ...